Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma

Abstract

Dysregulated Epiregulin (EREG) can activate epidermal growth factor receptor (EGFR) and promote tumor progression in head and neck squamous cell carcinoma (HNSCC). However, the mechanisms underlying EREG dysregulation remain largely unknown. Here, we showed that dysregulated EREG was highly associated with enhanced PDL1 in HNSCC tissues. Treatment of HNSCC cells with EREG resulted in upregulated PDL1 via the c-myc pathway. Of note, we found that N-glycosylation of EREG was essential for its stability, membrane location, biological function, and upregulation of its downstream target PDL1 in HNSCC. EREG was glycosylated at N47 via STT3B glycosyltransferases, whereas mutations at N47 site abrogated N-glycosylation and destabilized EREG. Consistently, knockdown of STT3B suppressed glycosylated EREG and inhibited PDL1 in HNSCC cells. Moreover, treatment of HNSCC cells with NGI-1, an inhibitor of STT3B, blocked STT3B-mediated glycosylation of EREG, leading to its degradation and suppression of PDL1. Finally, combination of NGI-1 treatment with anti-PDLl therapy synergistically enhanced the efficacy of immunotherapy of HNSCC in vivo. Taken together, STT3B-mediated N-glycosylation is essential for stabilization of EREG, which mediates PDL1 upregulation and immune evasion in HNSCC.

References

1. Mody M. D., Rocco J. W., Yom S. S., Haddad R. I.& Saba, N. F. Head and neck cancer.Lancet 398, 2289-2299 (2021).
2. Leemans, C. R., Snijders, P. J.F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer.Nat. Rev. Cancer 18, 269-282 (2018).
3. Cavalieri, S.et al.Immuno-oncology in head and neck squamous cell cancers: news from clinical trials, emerging predictive factors and unmet needs.Cancer Treat. Rev. 65, 78-86 (2018).
4. Ferris, R. L.et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck.N. Engl. J. Med. 375, 1856-1867 (2016).
5. Concha-Benavente, F. et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer.Cancer Res. 76, 1031-1043 (2016).
6. Du, L.et al.beta-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J. Exp. Med. 217, https://doi.org/10.1084/jem.20191115(2020).
7. Azuma, K.et al.Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.Ann. Oncol. 25, 1935-1940 (2014).
8. Akbay, E. A.et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discov. 3, 1355-1363 (2013).
9. Huang, C.et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39, 361-379.e316 (2021).
10. Toyoda, H.et al.Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes.J. Biol. Chem. 270, 7495-7500 (1995).
11. Liu, S.et al.Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma.Oncotarget 7, 25251-25263 (2016).
12. Liu, S.et al.EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.Theranostics 10, 10589-10605 (2020).
13. Yang, J.et al.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.Nature 586, 572-577 (2020).
14. Song M. J., Lee S. H., Kim E. Y.& Chang, Y. S. Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes.Transl. Lung Cancer Res. 9, 659-669 (2020).
15. Tang L.Detecting protein glycosylation.Nat. Methods 16, 26(2019).
16. Aebi M.N-linked protein glycosylation in the ER.Biochim. Biophys. Acta 1833, 2430-2437 (2013).
17. Mulagapati, S., Koppolu, V.& Raju, T. S. Decoding of O-linked glycosylation by mass spectrometry.Biochemistry 56, 1218-1226 (2017).
18. Arigoni-Affolter, I. et al. Mechanistic reconstruction of glycoprotein secretion through monitoring of intracellular N-glycan processing.Sci. Adv. 5, eaax8930 (2019).
19. Asano N.Glycosidase inhibitors: update and perspectives on practical use.Glycobiology 13, 93R-104R (2003).
20. Schwarz F.& Aebi, M. Mechanisms and principles of N-linked protein glycosylation.Curr. Opin. Struct. Biol. 21, 576-582 (2011).
21. Breitling J.& Aebi, M. N-linked protein glycosylation in the endoplasmic reticulum.Cold Spring Harb. Perspect. Biol. 5, a013359(2013).
22. Ruiz-Canada, C., Kelleher, D. J. & Gilmore, R. Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms.Cell 136, 272-283 (2009).
23. Hsu, J. M.et al.STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.Nat. Commun. 9, 1908(2018).
24. Casey, S. C.et al.MYC regulates the antitumor immune response through CD47 and PD-L1.Science 352, 227-231 (2016).
25. Delmore, J. E.et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc.Cell 146, 904-917 (2011).
26. Lopez-Sambrooks, C. et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.Nat. Chem. Biol. 12, 1023-1030 (2016).
27. Baro M.,Lopez Sambrooks, C., Quijano, A., Saltzman, W. M. & Contessa, J. Oligosaccharyltransferase inhibition reduces receptor tyrosine kinase activation and enhances glioma radiosensitivity.Clin. Cancer Res. 25, 784-795 (2019).
28. Song, X.et al.Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers.Cancer Discov. 10, 1872-1893 (2020).
29. Wang Y. N., Lee H. H., Hsu J. L., Yu D.& Hung, M. C. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.J. Biomed. Sci. 27, 77(2020).
30. Li, C. W.et al.Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.Nat. Commun. 7, 12632(2016).
31. Li, C. W.et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187-201.e110 (2018).
32. Sun, C., Mezzadra, R.& Schumacher, T. N. Regulation and function of the PD-L1 checkpoint.Immunity 48, 434-452 (2018).
33. Iwai, Y.et al.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
34. Herbst, R. S.et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature 515, 563-567 (2014).
35. Yang, Y.et al.Palmitoylation stabilizes PD-L1 to promote breast tumor growth.Cell Res. 29, 83-86 (2019).
36. Hsu J. M., Li C. W., Lai Y. J.& Hung, M. C. Posttranslational modifications of PD-L1 and their applications in cancer therapy.Cancer Res. 78, 6349-6353 (2018).
37. Cha, J. H.et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol. Cell 71, 606-620.e607 (2018).
38. Freed, D. M.et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell 171, 683-695.e618 (2017).
39. Zheng, H.et al.HDAC inhibitors enhance t-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma.Clin. Cancer Res. 22, 4119-4132 (2016).
40. Han, Y.et al.Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade.Cell Death Dis. 12, 993(2021).